Research Papers:

This article has been corrected. Correction in: Oncotarget. 2023; 14:215-215.

Annexin A13 promotes tumor cell invasion in vitro and is associated with metastasis in human colorectal cancer

Guozhong Jiang, Pengju Wang, Weiwei Wang, Wencai Li, Liping Dai and Kuisheng Chen _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:21663-21673. https://doi.org/10.18632/oncotarget.15523

Metrics: PDF 1718 views  |   HTML 2887 views  |   ?  


Guozhong Jiang1,*, Pengju Wang2,*, Weiwei Wang1, Wencai Li1, Liping Dai3, Kuisheng Chen1

1Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China

2Sino-British Research Centre for Molecular Oncology, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, 450052, China

3Institute of Medical and Pharmaceutical Sciences in Zhengzhou University, Zhengzhou, 450052, China

*These authors have contributed equally to this work

Correspondence to:

Kuisheng Chen, email: [email protected]

Liping Dai, email: [email protected]

Keywords: annexin A13, cell invasion, metastasis, colorectal cancer

Received: April 26, 2016     Accepted: January 27, 2017     Published: February 20, 2017


Purpose: Aberrantly upregulated expression of selected members of annexin, a group of calcium- and membrane-binding proteins, have been found to be associated with metastasis, poor prognosis, and other clinical characteristics in colorectal cancer (CRC), the third most diagnosed cancer. However, ANXA13 (encoding protein annexin A13), the original founder gene of the annexin A family, has not been studied carefully as a potential prognostic biomarker in CRC.

Methods: The protein level of annexin A13 was determined by western blot in a panel of CRC cell lines. Tumor cell invasion was determined by a Matrigel in vitro invasion assay in selected CRC cells with either upregulated (via plasmid transfection) or downregulated (via siRNA treatment) expression of ANXA13. The clinicopathological features and prognostic values associated with ANXA13 expression were also evaluated in a group of 125 CRC patients.

Results: ANXA13 was expressed at a high level in HCT116 and HT29 cells but undetected or at a lower level in SW620, SW48, and Rko cells. CRC cell invasion was promoted by ANXA13 overexpression in SW620 or Rko cells and was reduced by ANXA13 downregulation in HCT116 or HT29 cells. In CRC patients, ANXA13 expression levels correlated with lymph node metastasis and were associated with poor overall survival.

Conclusions: ANXA13 is associated with CRC cell invasion in vitro, and with lymph node metastasis and poor survival in CRC patients. Our results indicate that ANXA13 can be exploited as a biomarker for its diagnostic and prognostic values.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15523